Breckenridge Pharmaceutical Initiates Voluntary Recall
Breckenridge Pharmaceutical, Inc., located in Berkeley Heights, NJ, has announced a voluntary recall affecting one specific lot of its Propranolol Hydrochloride Extended-Release Capsules (USP), 60 mg. The decision comes after concerns were raised about potential metal contamination. This recalled lot was manufactured by Adare Pharma Solutions and had distribution nationwide, reaching pharmacies and wholesalers between October 26 and November 4, 2026.
Nature of the Recall
The recalled medication is identified as Propranolol Hydrochloride Extended-Release Capsules in 100-count bottles, carrying the NDC number 51991-817-01 and a lot number of PK25110035, with an expiration date set for May 2029. The potential risk arises from an intermediate material linked to metal contamination that was initially identified in a different, unreleased lot. While there have been no adverse events reportedly connected to this recall, the risk remains significant, as ingestion of contaminated capsules could lead to laceration of soft tissues in the mouth, esophagus, stomach, or intestines.
What Consumers Should Do
Consumers who possess this medication are strongly advised to cease usage of any capsules from the affected lot immediately. It is imperative to contact a healthcare professional for guidance, especially if you suspect any adverse effects from prior use. Any unused medication should be returned to the pharmacy where it was initially obtained.
Healthcare providers are encouraged to notify patients of this recall and ensure that any affected products are quarantined and not dispensed. Pharmacies and wholesalers must check their inventories for the recalled lot, isolate any affected products, and refrain from further distribution or dispensation. Notifying any sub-accounts of the distribution chain is also crucial for a comprehensive response to this recall.
Reporting Adverse Reactions
If anyone has experienced issues believed to be related to this product, they are urged to report these incidents to the FDA’s MedWatch Adverse Event Reporting program via their online system or through mail or fax. Detailed guidance on reporting adverse events can be found on the
FDA website.
Contact Information
Consumers and retailers with any inquiries can reach out to Breckenridge Pharmaceutical’s designated recall service provider, Qualanex, at 1-855-736-0807 during business hours. Additionally, you may email
[email protected] for further assistance.
This recall is enacted in compliance with regulatory standards and under the oversight of the U.S. Food and Drug Administration (FDA).
As a trusted name in the pharmaceutical industry, Breckenridge Pharmaceutical remains committed to ensuring the safety and health of its consumers. Ensuring that all medications provided to the public meet strict quality standards is vital, and any actions taken, such as this recall, reflect the company’s dedication to consumer safety.